Ironwood Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary - Moby Strategic Execution and Performance Drivers Delivered 11% LINZESS prescription demand growth in 2025, maintaining a 45% market share despite net price erosion from Medicare Part D redesign. Strategic reduction of LINZESS list price effective January 1, 2026, was implemented to preserve broad patient access amid evolving healthcare dynamics. Secured FDA alignment on the STARS II confirmatory Phase III trial for aproglutide, leveragin ...